Genitourinary tumours, non-prostate
Invited discussant abstracts 773PD, 774PD, 775PD and 776PD
Date
09 Oct 2016Session
Genitourinary tumours, non-prostatePresenters
Manuela SchmidingerAuthors
M. SchmidingerAuthor affiliations
- Vienna General Hospital (AKH) - Medizinische Universität Wien, 1090 - Vienna/AT
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
3309 - Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: Results from the phase II CheckMate 275 study
Presenter: Matthew Galsky
Session: Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
2626 - Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study
Presenter: Arjun Balar
Session: Genitourinary tumours, non-prostate
Resources:
Abstract
Immunotherapy will be “THE OPTION” in first and second line urothelial tumors
Presenter: Laurence Albiges
Session: Genitourinary tumours, non-prostate
Resources:
Slides
Webcast
Chemotherapy will always remain “THE BACKBONE” in urothelial tumor
Presenter: Viktor Grünwald
Session: Genitourinary tumours, non-prostate
Resources:
Slides
Webcast
2577 - Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results
Presenter: Michael Atkins
Session: Genitourinary tumours, non-prostate
Resources:
Abstract
4232 - A phase I study of cabozantinib plus nivolumab (CaboNivo) in patients (pts) refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors
Presenter: Andrea Apolo
Session: Genitourinary tumours, non-prostate
Resources:
Abstract
2513 - Phase 1b dose-finding study of avelumab (anti-PD-L1) + axitinib in treatment-naïve patients with advanced renal cell carcinoma
Presenter: James Larkin
Session: Genitourinary tumours, non-prostate
Resources:
Abstract
1779 - A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients with selected solid tumors
Presenter: Matthew Taylor
Session: Genitourinary tumours, non-prostate
Resources:
Abstract
2534 - Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma progressed after platinum-based therapy or platinum ineligible
Presenter: Manish Patel
Session: Genitourinary tumours, non-prostate
Resources:
Abstract
1888 - Quality of life (QoL) and neurotoxicity in germ-cell cancer survivors (GCCS)
Presenter: Jakob Lauritsen
Session: Genitourinary tumours, non-prostate
Resources:
Abstract
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.